MDT-AP-3050
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 30.8
- sex
- M
- new_clusters
- S1
- umap1_2d
- -0.277642464
- umap2_2d
- -10.79408915
- umap1_3d
- -3.607393109
- umap2_3d
- 0.055967075
- umap3_3d
- 6.311971121
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.420
- INTERFERON_ALPHA_RESPONSE+0.400
- PROTEIN_SECRETION+0.400
- INTERFERON_GAMMA_RESPONSE+0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- UV_RESPONSE_DN+0.330
- TGF_BETA_SIGNALING+0.300
- OXIDATIVE_PHOSPHORYLATION+0.280
- MITOTIC_SPINDLE+0.270
- ANDROGEN_RESPONSE+0.260
Top 10 suppressed
- KRAS_SIGNALING_DN-0.280
- PANCREAS_BETA_CELLS-0.250
- APICAL_SURFACE-0.230
- ESTROGEN_RESPONSE_LATE-0.220
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.190
- HEDGEHOG_SIGNALING-0.140
- ANGIOGENESIS-0.120
- SPERMATOGENESIS-0.120
- MYOGENESIS-0.110
- BILE_ACID_METABOLISM-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934922 | — | — | 0.846 |
| 2 | SRR934930 | — | — | 0.844 |
| 3 | E6AA40DA-9AB7-478B-B46B-827F9AFE52D1 | — | — | 0.835 |
| 4 | AB522ACF-5D84-41B0-9671-CE2511EBD94F | — | — | 0.832 |
| 5 | SRR934942 | — | — | 0.828 |
| 6 | MDT-AP-3324 | Med | Medulloblastoma | 0.823 |
| 7 | SRR934827 | — | — | 0.822 |
| 8 | SRR934925 | — | — | 0.819 |
| 9 | SRR934895 | — | — | 0.813 |
| 10 | MNG240 | — | — | 0.810 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |